We spoke with Eric Schuur, President and CEO of HepaTx, to learn how the company hopes to develop regenerative medicine solutions for people with liver disease. Eric provides an overview of the steps involved in hepatocyte production and provides insights on the hurdles that need to be overcome, to get these stem cells from the lab to the clinic.Read More
Loud background noise doesn’t just annoy people by getting in the way of good conversation – it also affects voice activated devices. AudioTelligence, a start-up based out of Cambridge, say they have developed the world’s first digital solution to this ‘cocktail party problem’.
Whilst all life sciences have benefited immensely from digitization and automation in the last ten years, tools designed specifically for biologists have been somewhat scarce. London-based Synthace are aiming to change that. In this blog, we ask Synthace co-founder Chris Grant how his company's platform Antha was developed and why it has earned Synthace a “Cool Vendor of the Year” award from Gartner.Read More
Next-generation sequencing has revolutionized science by significantly increasing the speed and volume of data that can be generated for a given genome. As NGS technologies have become more affordable, in-house sequencing has become more popular, shifting away from outsourced projects using service providers. In this blog, Thermo Fisher Scientific’s Karen Velardi explains how labs and users can utilize data management techniques to get the most from their NGS results.
Biomarkers hold immense potential for the future of medicine, enabling more efficient and better-targeted treatments. Most coverage of novel biomarkers to date has been focused on how a patient’s genetic signature can indicate their susceptibility to a disease, but there is a world of other biological and environmental information that can impact how patients respond to treatments. In this blog, SCIEX’s Aaron Hudson explains how non-genetic biomarkers have a key role to play in reaching the goal of truly precise medicine.
Cell-Free Technology is taking a unique approach to protein technology with their BioBits initiative, which they say combines the ease of use of a digital design tool with the detailed scientific validation provided by a CRO. We catch up with Cell-Free CEO Tom Meany to discuss the new technology.Read More
There are approximately 7,000 known rare diseases, however, less than 6% of these have a treatment. It is estimated that between 25–35 million Americans live with a rare disease. The company ProQR is dedicated to developing new therapeutics for patients living with untreated rare diseases. We caught up with Daniel de Boer, Chief Executive Officer at ProQR to learn more about the company’s approach to finding new treatments for rare genetic diseases.Read More
As researchers explore therapeutic strategies for more complex and heterogeneous diseases the need for more physiologically relevant models has never been greater. Researchers are increasingly looking to 3D cell cultures, spheroids, organoids and microtissues to bridge the gap between 2D cell cultures and in vivo animal models.Read More